Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28643037 | 0.81 | TACR1 (0.56) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL15701190 | 0.77 | TSHR (0.56) | TACR1SMN1; SMN2HTTTSHRNPC1 | |
| SCHEMBL1521021 | 0.76 | TACR1 (0.59) | TACR1TSHRCA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL11129793 | 0.76 | TSHR (0.54) | TACR1SMN1; SMN2HTTTSHRNPC1 | |
| Hydrochloric Acid SCHEMBL14686335 | 0.74 | TACR1 (0.57) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL11129540 | 0.71 | TSHR (0.52) | SMN1; SMN2HTTTSHRNPC1KDM1A | |
| SCHEMBL16321476 | 0.70 | TACR1 (0.70) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL4988525 | 0.70 | TACR1 (0.70) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL18580091 | 0.70 | TACR1 (0.70) | TACR1TSHRCA1CA2CA7 | |
| SCHEMBL13401110 | 0.69 | TSHR (0.50) | SMN1; SMN2HTTTSHRNPC1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1960999-A | Process for preparing indolopyrrolocarbazole derivatives | BANYU PHARMA CO LTD (JP) | 2007-05-09 | — | — | CN | disclosed |
| CN-1185247-C | Process for producing indolopyrrolocarbazole derivative, intermediate for the production, and process for producing the intermediate | BANYU PHARMA CO LTD (JP) | 2005-01-19 | — | — | CN | disclosed |
| US-6790836-B2 | Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030060621-A1 | Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| CN-1400976-A | Process for producing indolopyrrolocarbazole derivative, intermediate for the production, and process for producing the intermediate | BANYU PHARMA CO LTD (JP) | 2003-03-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060621-A1 | Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates | WEE1, CYP4B1, CYP3A4 | TACR1 3971/4885SMN1; SMN2 4816/4885HTT 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.